Alexander I. Spira, David Sommerhalder, Annie Winterhall, Tonia Jane Buchholz, Tarah Bateman, David G. Kugler, Dan Rock, Olatunji B. Alese, David Berz, Marwan Fakih, Joel R. Hecht, David Yoonsuk Oh, Manish R. Sharma, Christina Wu, Dirk Nagorsen. "A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/microsatellite instability–low (MSI-L) colorectal cancer (CRC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps3678